CD137 expression is induced by Epstein-barr virus infection through LMP1 in T or NK cells and mediates survival promoting signals

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Yoshimori, Mayumi ^a   Imadome, Ken Ichi ^b   Komatsu, Honami ^a   Wang, Ludan ^a   Saitoh, Yasunori ^a   Yamaoka, Shoji ^a   Fukuda, Tetsuya ^a   Kurata, Morito ^a   Koyama, Takatoshi ^a   Shimizu, Norio ^a   Fujiwara, Shigeyoshi ^b   Miura, Osamu ^a   Arai, Ayako ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 ANTIGEN; ETOPOSIDE; PROTEIN LMP1; UNCLASSIFIED DRUG; VIRUS PROTEIN; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; INTERLEUKIN 2; MATRIX PROTEIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD137 GENE; CELL DEATH; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS INFECTION; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LMP1 GENE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MALE; MIDDLE AGED; MOUSE; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; SCHOOL CHILD; SIGNAL TRANSDUCTION; T LYMPHOCYTE; UPREGULATION; VIRUS GENE; VIRUS INDUCTION; YOUNG ADULT; ADOLESCENT; CELL LINE; CELL SURVIVAL; CYTOLOGY; DRUG EFFECTS; EPSTEIN BARR VIRUS; IMMUNOLOGY; LYMPHOPROLIFERATIVE DISEASE; METABOLISM; VIROLOGY;

HUMAN HERPESVIRUS 4;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD137; CELL LINE; CELL SURVIVAL; CHILD; FEMALE; GENE EXPRESSION REGULATION; HERPESVIRUS 4, HUMAN; HUMANS; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; VIRAL MATRIX PROTEINS; YOUNG ADULT;

EID: 84918800175     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112564     Document Type: Article

References (57)

1. Chan JKC, Quintanilla-Martinez L, Ferry JA, Peh S-C (2008) Extranodal NK/ T-cell lymphoma, nasal type. In: Jaffe E, Harris N, Stein H, editors. World Health Organization Classification of Tumors Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon IARC Press. pp. 285-289.
2. Chan JKC, Jaffe ES, Ralfkiaer E, Ko Y-H (2008) Aggressive NK-cell leukemia. In: ES J, NL H, H S, editors. World Health Organization Classification of Tumors Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press. pp. 276-277.
3. Quintanilla-Martinez L, Kimura H, Jaffe ES (2008) EBV-positive T-cell lymphoproliferative disorders of childhood. In: Jaffe E, Harris N, Stein H, editors. World Health Organization Classification of Tumors Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues.Lyon IARC Press. pp. 278-280.
4. Kimura H, Ito Y, Kawabe S, Gotoh K, Takahashi Y, et al. (2012) EBVassociated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood 119: 673-686.
5. Kimura H, Hoshino Y, Kanegane H, Tsuge I, Okamura T, et al. (2001) Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood 98: 280-286.
6. Arai A, Imadome K, Watanabe Y, Yoshimori M, Koyama T, et al. (2011) Clinical features of adult-onset chronic active Epstein-Barr virus infection: a retrospective analysis. Int J Hematol 93: 602-609.
7. Kawa K, Sawada A, Sato M, Okamura T, Sakata N, et al. (2011) Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection. Bone Marrow Transplant 46: 77-83.
8. Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, et al. (2011) Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 29: 4410-4416.
9. Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, et al. (2012) Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: An Updated Analysis of the Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol.
10. Croft M (2009) The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 9: 271-285.
11. Pollok KE, Kim YJ, Zhou Z, Hurtado J, Kim KK, et al. (1993) Inducible T cell antigen 4-1BB. Analysis of expression and function. J Immunol 150: 771-781.
12. Pichler K, Kattan T, Gentzsch J, Kress AK, Taylor GP, et al. (2008) Strong induction of 4-1BB, a growth and survival promoting costimulatory receptor, in HTLV-1-infected cultured and patients' T cells by the viral Tax oncoprotein. Blood 111: 4741-4751.
13. Anderson MW, Zhao S, Freud AG, Czerwinski DK, Kohrt H, et al. (2012) CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications. Am J Pathol 181: 795-803.
14. Zhang Y, Nagata H, Ikeuchi T, Mukai H, Oyoshi MK, et al. (2003) Common cytological and cytogenetic features of Epstein-Barr virus (EBV)-positive natural killer (NK) cells and cell lines derived from patients with nasal T/NK-cell lymphomas, chronic active EBV infection and hydroa vacciniforme-like eruptions. Br J Haematol 121: 805-814.
15. Imadome K, Yajima M, Arai A, Nakazawa A, Kawano F, et al. (2011) Novel Mouse Xenograft Models Reveal a Critical Role of CD4 T Cells in the Proliferation of EBV-Infected T and NK Cells. PLoS Pathog 7: e1002326.
16. Tan JT, Ha J, Cho HR, Tucker-Burden C, Hendrix RC, et al. (2000) Analysis of expression and function of the costimulatory molecule 4-1BB in alloimmune responses. Transplantation 70: 175-183.
17. Lee HW, Park SJ, Choi BK, Kim HH, Nam KO, et al. (2002) 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J Immunol 169: 4882-4888.
18. Takahara M, Kis LL, Nagy N, Liu A, Harabuchi Y, et al. (2006) Concomitant increase of LMP1 and CD25 (IL-2-receptor alpha) expression induced by IL-10 in the EBV-positive NK lines SNK6 and KAI3. Int J Cancer 119: 2775-2783.
19. Ohga S, Nomura A, Takada H, Ihara K, Kawakami K, et al. (2001) Epstein-Barr virus (EBV) load and cytokine gene expression in activated T cells of chronic active EBV infection. J Infect Dis 183: 1-7.
20. Yamanaka Y, Tagawa H, Takahashi N, Watanabe A, Guo YM, et al. (2009) Aberrant overexpression of microRNAs activate AKT signaling via downregulation of tumor suppressors in natural killer-cell lymphoma/leukemia. Blood 114: 3265-3275.
21. Kutz H, Reisbach G, Schultheiss U, Kieser A (2008) The c-Jun N-terminal kinase pathway is critical for cell transformation by the latent membrane protein 1 of Epstein-Barr virus. Virology 371: 246-256.
22. Eliopoulos AG, Gallagher NJ, Blake SM, Dawson CW, Young LS (1999) Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J Biol Chem 274: 16085-16096.
23. Dawson CW, Laverick L, Morris MA, Tramoutanis G, Young LS (2008) Epstein-Barr virus-encoded LMP1 regulates epithelial cell motility and invasion via the ERK-MAPK pathway. J Virol 82: 3654-3664.
24. Kaye KM, Izumi KM, Li H, Johannsen E, Davidson D, et al. (1999) An Epstein-Barr virus that expresses only the first 231 LMP1 amino acids efficiently initiates primary B-lymphocyte growth transformation. J Virol 73: 10525-10530.
25. Kim JO, Kim HW, Baek KM, Kang CY (2003) NF-kappaB and AP-1 regulate activation-dependent CD137 (4-1BB) expression in T cells. FEBS Lett 541: 163-170.
26. Imadome K, Shirakata M, Shimizu N, Nonoyama S, Yamanashi Y (2003) CD40 ligand is a critical effector of Epstein-Barr virus in host cell survival and transformation. Proc Natl Acad Sci U S A 100: 7836-7840.
27. Imadome K, Shimizu N, Arai A, Miura O, Watanabe K, et al. (2005) Coexpression of CD40 and CD40 ligand in Epstein-Barr virus-infected T and NK cells and their role in cell survival. J Infect Dis 192: 1340-1348.
28. Mukundan L, Bishop GA, Head KZ, Zhang L, Wahl LM, et al. (2005) TNF receptor-associated factor 6 is an essential mediator of CD40-activated proinflammatory pathways in monocytes and macrophages. J Immunol 174: 1081-1090.
29. Song Z, Jin R, Yu S, Rivet JJ, Smyth SS, et al. (2011) CD40 is essential in the upregulation of TRAF proteins and NF-kappaB-dependent proinflammatory gene expression after arterial injury. PLoS One 6: e23239.
30. Nakaima Y, Watanabe K, Koyama T, Miura O, Fukuda T (2013) CD137 Is Induced by the CD40 Signal on Chronic Lymphocytic Leukemia B Cells and Transduces the Survival Signal via NF-κB Activation. PLoS One 8: e64425.
31. Salih HR, Kosowski SG, Haluska VF, Starling GC, Loo DT, et al. (2000) Constitutive expression of functional 4-1BB (CD137) ligand on carcinoma cells. J Immunol 165: 2903-2910.
32. Alderson MR, Smith CA, Tough TW, Davis-Smith T, Armitage RJ, et al. (1994) Molecular and biological characterization of human 4-1BB and its ligand. Eur J Immunol 24: 2219-2227.
33. Pollok KE, Kim YJ, Hurtado J, Zhou Z, Kim KK, et al. (1994) 4-1BB T-cell antigen binds to mature B cells and macrophages, and costimulates anti-muprimed splenic B cells. Eur J Immunol 24: 367-374.
34. Salih HR, Schmetzer HM, Burke C, Starling GC, Dunn R, et al. (2001) Soluble CD137 (4-1BB) ligand is released following leukocyte activation and is found in sera of patients with hematological malignancies. J Immunol 167: 4059-4066.
35. Jung HW, Choi SW, Choi JI, Kwon BS (2004) Serum concentrations of soluble 4-1BB and 4-1BB ligand correlated with the disease severity in rheumatoid arthritis. Exp Mol Med 36: 13-22.
36. Hentschel N, Krusch M, Kiener PA, Kolb HJ, Salih HR, et al. (2006) Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma. Eur J Haematol 77: 91-101.
37. Kimura H (2006) Pathogenesis of chronic active Epstein-Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency? Rev Med Virol 16: 251-261.
38. Kasahara Y, Yachie A, Takei K, Kanegane C, Okada K, et al. (2001) Differential cellular targets of Epstein-Barr virus (EBV) infection between acute EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Blood 98: 1882-1888.
39. Fox CP, Shannon-Lowe C, Gothard P, Kishore B, Neilson J, et al. (2010) Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults characterized by high viral genome load within circulating natural killer cells. Clin Infect Dis 51: 66-69.
40. Shao Z, Schwarz H (2011) CD137 ligand, a member of the tumor necrosis factor family, regulates immune responses via reverse signal transduction. J Leukoc Biol 89: 21-29.
41. Lee SW, Park Y, So T, Kwon BS, Cheroutre H, et al. (2008) Identification of regulatory functions for 4-1BB and 4-1BBL in myelopoiesis and the development of dendritic cells. Nat Immunol 9: 917-926.
42. Laderach D, Wesa A, Galy A (2003) 4-1BB-ligand is regulated on human dendritic cells and induces the production of IL-12. Cell Immunol 226: 37-44.
43. Pauly S, Broll K, Wittmann M, Giegerich G, Schwarz H (2002) CD137 is expressed by follicular dendritic cells and costimulates B lymphocyte activation in germinal centers. J Leukoc Biol 72: 35-42.
44. Middendorp S, Xiao Y, Song JY, Peperzak V, Krijger PH, et al. (2009) Mice deficient for CD137 ligand are predisposed to develop germinal center-derived B-cell lymphoma. Blood 114: 2280-2289.
45. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, et al. (1997) Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 3: 682-685.
46. Narazaki H, Zhu Y, Luo L, Zhu G, Chen L (2010) CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells. Blood 115: 1941-1948.
47. Seo SK, Choi JH, Kim YH, Kang WJ, Park HY, et al. (2004) 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med 10: 1088-1094.
48. Miki T, Kawamata N, Arai A, Ohashi K, Nakamura Y, et al. (1994) Molecular cloning of the breakpoint for 3q27 translocation in B-cell lymphomas and leukemias. Blood 83: 217-222.
49. Okano M, Kawa K, Kimura H, Yachie A, Wakiguchi H, et al. (2005) Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection. Am J Hematol 80: 64-69.
50. Kimura H, Morita M, Yabuta Y, Kuzushima K, Kato K, et al. (1999) Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol 37: 132-136.
51. Sinclair AJ, Palmero I, Peters G, Farrell PJ (1994) EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO J 13: 3321-3328.
52. Reedman BM, Klein G (1973) Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. Int J Cancer 11: 499-520.
53. Shirakata M, Imadome KI, Okazaki K, Hirai K (2001) Activation of TRAF5 and TRAF6 signal cascades negatively regulates the latent replication origin of Epstein-Barr virus through p38 mitogen-activated protein kinase. J Virol 75: 5059-5068.
54. Nosaka Y, Arai A, Miyasaka N, Miura O (1999) CrkL mediates Ras-dependent activation of the Raf/ERK pathway through the guanine nucleotide exchange factor C3G in hematopoietic cells stimulated with erythropoietin or interleukin-3. J Biol Chem 274: 30154-30162.
55. MacCallum CJ (2010) Reporting animal studies: good science and a duty of care. PLoS Biol 8: e1000413.
56. Iwasaki Y, Chong JM, Hayashi Y, Ikeno R, Arai K, et al. (1998) Establishment and characterization of a human Epstein-Barr virus-associated gastric carcinoma in SCID mice. J Virol 72: 8321-8326.
57. Takada K, Horinouchi K, Ono Y, Aya T, Osato T, et al. (1991) An Epstein-Barr virus-producer line Akata: establishment of the cell line and analysis of viral DNA. Virus Genes 5: 147-156.